Klaudia P.’s Post

Uncover insights into #DAPT duration post-flow diverter treatment. Dr. Jildaz CAROFF shares findings from an analysis involving 700 patients, revealing peaks in DAPT length and excellent safety outcomes. Optimize therapeutic strategies based on real-world evidence! https://ow.ly/ozHh50QCLT8

Real-World Data: Optimizing Treatments Beyond the Lab Clinical trials are very important for drug viability but they don't tell the whole story. Real-world evidence (RWE) is gathered to capture how patients actually use treatments. This data helps enhance outcomes in: Adherence: RWE reveals real-life medication use patterns, informing better support programs. Cost-Effectiveness: By analyzing real-world costs, we make smarter resource allocation choices. Think novel rare disease treatments: Clinical trials look good, but RWE shows high missed doses. This info can lead to better delivery methods or reminders, ultimately improving patient outcomes. RWE + Clinical Trials = A clearer picture of treatment effectiveness for better patient care! #healthcare #RWE

🎊 We would like to invite you to read an #article "Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for #Vancomycin in Elderly Patients" by Howard Lee, et al. Journal of Personalized Medicine MDPI link here: https://lnkd.in/gid4AY6V

Important analysis from Simone Villa, Pierpaolo de Colombani, Lucia Dall’Olio, Giuliano Gargioni, and Mario Raviglione presenting crucial #policy recommendations aimed at enhancing clinical trials for new #tuberculosis drug regimens. This comprehensive approach could significantly impact TB treatment and control efforts globally. 👉 Read the full paper for in-depth insights and implications: https://lnkd.in/ekHiNyRg #TBResearch #ClinicalTrials #GlobalHealth UNITE4TB Innovative Health Initiative (IHI)

Did you know, alcohol-associated #hepatitis (#AH) causes more than ~164,000 hospitalizations per year? With the rate of #AH rising, there is an unmet need for novel therapeutic strategies to improve survival rates. At DURECT, we’re leading therapeutic innovation. Learn more here: https://bit.ly/3X52KAj #LiverAwarenessMonth

The success of your drug development relies on access to proven Parkinson’s disease expertise and robust processes and technologies to enhance your trial design and accelerate development. Clario's globally recognized scientific and medical experts provide the evidence you need to address challenges such as: ▫️ Early disease detection for timely treatment intervention with investigational treatments ▫️ Accounting for significant person-to-person differences in your study design ▫️ Strategies for accelerating timelines ▫️ Optimizing your clinical outcome measures ➡️ Watch our webinar to learn how Clario can help you navigate your Parkinson's trial more effectively. https://lnkd.in/d9ts99XD #ClinicalTrials #ParkinsonsDisease

Salman Fazal, MD; Yvonne Efebera, MD; Sumit Madan, MD, Ruemu Birhiray, MD, discuss how evaluating real-world efficacy and safety outcomes of GPRC5D-targeted therapies, along with identifying practical challenges and considerations, can guide the implementation of bispecifics in community practices. https://lnkd.in/egNMkkY4

Key End Points in Clinical Trials: Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations. #finance #pharmacy #lifesciences

In this cohort study with up to 5 years of follow-up, dupilumab maintained its clinical effectiveness, while two-thirds of patients tapered to a dosing interval of every 3 or 4 weeks. https://ja.ma/3yCtPRu

Compassionate use programs play a crucial, yet often underappreciated, role in drug development; providing patients, particularly those with rare diseases, access to potentially life-saving therapies that may positively impact the trajectory of their health outcomes.   We're thrilled to publish, in partnership with WEP Clinical and Ana Paula Tediosi, this two-part series on compassionate use programs and the meaningful benefits in the development of a potential treatment for multiple forms of insulin receptor mediated hypoglycemia. https://bit.ly/4eXiL0O #clinicaltrials #clinicalresearch #raredisease #hypoglycemiaawarenessweek